Rhopressa
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.rhopressa.comRevenue
$6.9 MillionIndustry
About Rhopressa
Is Rhopressa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Rhopressa launches new products
Congratulate Masked Content for being promoted to Masked Content at Rhopressa
Check if Rhopressa has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Rhopressa has new funding data
Website visits: Recent activity has been detected on your website
Check out if Rhopressa is spiking on competitors!
Rhopressa, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Rhopressa recently announced quarterly report
Click to see if Rhopressa had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Rhopressa as Masked Content
Find 3 more new buyers
Compare Similar Companies to Rhopressa
Compare insights from companies similar to Rhopressa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Rhopressa
Rhopressa Tech Stack
A closer look at the technologies used by Rhopressa
Rhopressa News & Media
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries
OSAKA, Japan & DURHAM, N.C.--(BUSINESS WIRE)--Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa® and Rocklatan® in Japan, along with rights for several other Asian countries. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment ofAerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that its sterile fill production facility in Athlone, Ireland has received approval from the U.S. Food and Drug Administration (FDA) for production of Rhopressa® (netarsudil ophthal
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rhopressa
Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Contact Lenses: Contact lenses... Read More